Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherap (NQ: ATRA )

0.6786 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,504
Open 0.6786
Bid (Size) 0.6700 (1)
Ask (Size) 0.7059 (4)
Prev. Close 0.6786
Today's Range 0.6786 - 0.6786
52wk Range 0.1986 - 3.080
Shares Outstanding 101,102,152
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire

Performance

YTD
+41.40%
+41.40%
1 Month
+13.94%
+13.94%
3 Month
-4.84%
-4.84%
6 Month
-56.50%
-56.50%
1 Year
-77.60%
-77.60%

More News

Read More
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Atara Biotherapeutics: Q4 Earnings Insights
Via Benzinga
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
From Atara Biotherapeutics, Inc.
Via Business Wire
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Rocket Lab Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
From Atara Biotherapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.